Concurrent Investment Advisors LLC lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 20.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,742 shares of the medical instruments supplier’s stock after acquiring an additional 2,319 shares during the period. Concurrent Investment Advisors LLC’s holdings in Becton, Dickinson and Company were worth $2,367,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds also recently made changes to their positions in BDX. GQG Partners LLC bought a new stake in shares of Becton, Dickinson and Company during the first quarter valued at approximately $689,833,000. Vanguard Group Inc. raised its stake in Becton, Dickinson and Company by 4.7% during the 1st quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock valued at $6,414,322,000 after buying an additional 1,259,750 shares during the last quarter. Nuveen LLC purchased a new stake in Becton, Dickinson and Company during the 1st quarter valued at $211,097,000. Kingstone Capital Partners Texas LLC purchased a new stake in Becton, Dickinson and Company during the 2nd quarter valued at $155,080,000. Finally, Massachusetts Financial Services Co. MA raised its stake in Becton, Dickinson and Company by 10.8% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock valued at $1,567,654,000 after buying an additional 667,957 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.
Becton, Dickinson and Company Stock Up 0.9%
BDX opened at $188.31 on Wednesday. The firm has a 50-day simple moving average of $190.46 and a two-hundred day simple moving average of $185.47. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The company has a market capitalization of $53.97 billion, a PE ratio of 33.87, a price-to-earnings-growth ratio of 1.46 and a beta of 0.25. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69.
Becton, Dickinson and Company Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio is 74.82%.
Insider Transactions at Becton, Dickinson and Company
In related news, Director Claire Fraser sold 917 shares of the stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares of the company’s stock, valued at approximately $881,077.23. The trade was a 19.52% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 3,023 shares of company stock valued at $562,036. 0.36% of the stock is owned by insiders.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on BDX shares. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Wells Fargo & Company boosted their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research note on Friday, August 8th. Royal Bank Of Canada began coverage on shares of Becton, Dickinson and Company in a research note on Thursday, September 25th. They set a “sector perform” rating and a $211.00 target price for the company. Morgan Stanley upped their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $205.40.
Get Our Latest Research Report on BDX
Becton, Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
See Also
- Five stocks we like better than Becton, Dickinson and Company
- How to invest in marijuana stocks in 7 stepsĀ
- After Gold Blast Soars Past $4,000, BofA Eyes $5,000 in 2026
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Buyback Boom: 3 Companies Betting Big on Themselves
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Analysts Flock to Upgrade DELL After Big AI-Server Guidance Boost
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.